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-galactosidase activity, was observed in the thymus,
spleen, and lymph nodes but was negligible in bone
marrow of heterozygous mice (Figure 1D). Gating on
cells expressing different surface markers revealed
-galactosidase activity in CD4, CD8, and B220 cells
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but not in Mac-1 or Ter-119 cells (Figure 1E and data
not shown). These results suggest that CARMA1 expres-
sion within hemopoietic lineages is restricted toSummary
lymphoid cells.
Thymus, spleen, lymph node, and bone marrow cellu-CARMA1 (originally called CARD11) is a membrane-
larities were comparable between homozygous CARMA1associated guanylate kinase family member that is
mutant mice and their wild-type littermates. Flow-cyto-required for T cell receptor (TCR)-induced NF-B acti-
metric analysis of cells stained with antibodies to CD4vation in T cell leukemia lines [1–5]. It uses its N-ter-
and CD8 (data not shown) revealed no difference in theminal caspase activation and recruitment domain
frequency of CD48, CD48, and CD48 cells in the(CARD) to interact with the CARD in the downstream
thymus, spleen, lymph nodes, and peripheral blood,adaptor Bcl-10. We show that primary B and T lympho-
suggesting that T cell development can occur normallycytes from knock-in mice expressing only a CARDless
in the absence of wild-type CARMA1. The frequencyform of CARMA1 (CARD) are defective at mitogen-
of B220IgM cells in the spleen, lymph nodes, andinduced NF-B activation and fail to proliferate.
peripheral blood also was not altered significantly byCARMA1 mutant mice exhibited normal T but impaired
mutation of CARMA1 (data not shown). However, flow-B cell development; CD5 peritoneal B cells were
cytometric analysis of peritoneal cells from homozygousabsent, and serum immunoglobulin levels were mark-
CARMA1 mutant mice revealed a complete absence ofedly reduced. A lacZ reporter gene knocked into the
B220IgMCD5 B cells (Figure 2A). Another indicationCARMA1 locus confirmed lymphocyte-specific ex-
of impaired B cell development and function in thesepression of CARMA1. Thus, CARMA1 has an essential
mice was markedly reduced serum immunoglobulin lev-role in mediating B and T lymphocyte proliferation and
els (Figure 2B). IgM, IgG2b, and IgG3 isotypes in ninerequires its CARD to engage downstream signaling
out of nine naı¨ve mice and IgA in seven out of nine micecomponents.
were below the level of detection, and mean IgG1 and
IgG2a levels were down to 36%–40% of wild-type levels.
Results and Discussion B and T cell function in the absence of wild-type
CARMA1 also was assessed in terms of proliferation in
The importance of the N-terminal CARD in CARMA1 response to various mitogens in vitro. Purified homozy-
(includes murine amino acids 26–112) to signaling in the gous but not heterozygous CARMA1 mutant T cells
whole animal was determined with mice that express a showed defective proliferation when stimulated either
CARDless form of CARMA1 (CARD). A targeting vector with antibodies to CD3 and CD28 or with PMA and
that replaced the CARD-encoding exons 2 and 3 with ionomycin (Figure 3A). For example, after 4 days of CD3
a lacZ reporter gene and a PGK-neo cassette was de- and CD28 crosslinking, [3H]-thymidine uptake in wild-
signed (Figure 1A). Retention of the exon 2 splice ac- type and heterozygous cultures was maximal and aver-
ceptor site ahead of stop codons in all three reading aged 100,000 cpm, whereas uptake in homozygous mu-
frames and a consensus Kozak start site for the lacZ tant T cell cultures was negligible at less than 1000 cpm.
gene allowed -galactosidase expression (Figure 1D), We stained T cells that had been stimulated with anti-
and splicing of exon 1 to exon 4 maintained an open CD3 and anti-CD28 antibodies for 3 days with propid-
reading frame that allowed expression ofCARD (Figure ium iodide and annexin-V and analyzed them by flow
1C). A rat monoclonal antibody raised against amino cytometry to determine the percentage of apoptotic
acids 804–959 of mouse CARMA1 immunoprecipitated cells. Only 14% of homozygous CARMA1 mutant T cells
full-length CARMA1 (133 kDa) from wild-type spleen were not stained by either reagent and were therefore
cells and a smaller protein corresponding to CARD viable, as compared to 35% of wild-type T cells (Figure
(119 kDa) from homozygous CARMA1 mutant spleen 3C). In addition, those mutant T cells that remained via-
cells (Figure 1C). Equivalent amounts of full-length ble showed no evidence of cell growth as judged by
CARMA1 and CARD were recovered from heterozy- their forward light-scatter profile, which is an indication
gous CARMA1 mutant spleen cells. To determine the of cell size. By contrast, viable wild-type T cells showed
cell types that express CARMA1, we loaded cells from a significant increase in cell size (Figure 3C). These re-
heterozygous CARMA1 mutant mice and their wild-type sults indicate that the block in proliferation of CARMA1
littermates with the -galactosidase substrate fluores- mutant T cells occurs very early at a point preceding
cein di -D-galactopyranoside and analyzed them by cell growth. Cell viability, growth, and proliferation of
flow cytometry. Production of fluorescein, indicative of CARMA1 mutant T cells after CD3 and CD28 crosslink-
ing were largely restored by the addition of exogenous
interleukin-2 (IL-2; Figures 3A and 3C). These findings*Correspondence: dixit@gene.com
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Figure 1. Generation of CARMA1 Mutant
Mice
(A) Exons 2 and 3 encoding the CARD of
CARMA1 were replaced with a lacZ reporter
gene and a neomycin resistance cassette.
Stop codons inserted downstream of the exon
2 splice acceptor site and a consensus Kozak
translation initiation sequence for the lacZ
gene were used to promote -galactosidase
expression. Splicing of exon 1 to exon 4 gen-
erates an open reading frame that encodes
a “CARDless” form of CARMA1 (CARD).
(B) Southern blot analysis of HindIII/XbaI-
digested genomic DNA from wild-type (/),
heterozygous (/), and homozygous (/)
CARMA1 mutant mice was performed with a
probe encompassing exon 5. The 9.2 and 6.2
kb DNA fragments correspond to the wild-
type and targeted CARMA1 alleles, respec-
tively.
(C) Immunoprecipitation and Western blot
analysis of CARMA1 in spleen cells from
/, /, and / mice. CARMA1 protein
was immunoprecipitated and blotted with a
rat monoclonal antibody (clone 3B1.1.1) that
recognizes an epitope between amino acids
804 and 959 of mouse CARMA1. As a posi-
tive control, recombinant mouse CARMA1
(rCARMA1) with a 3 FLAG C-terminal epi-
tope tag was immunoprecipitated from tran-
siently transfected 293T cells. FL designates
the full-length CARMA1 protein with a pre-
dicted molecular weight of 133 kDa. CARD
indicates the CARMA1 “CARDless” form that
is produced by splicing exon 1 to exon 4 and
has a predicted molecular weight of 119 kDa.
The heavy and light chains of the immuno-
precipitating rat monoclonal antibodies are
marked with asterisks. An open arrowhead
indicates bands that we believe to be degra-
dation products of CARMA1 because they are
also detected by antibodies to the C-terminal
epitope tag of rCARMA1 (data not shown).
(D) Flow-cytometric analysis of -galactosidase
activity in thymus, spleen, lymph node, and
bone marrow cells from / and / mice.
(E) Flow-cytometric analysis of -galactosidase activity in cells from / and / mice after gating on CD4, CD8 or B220 spleen cells
and Mac-1 bone marrow cells. Solid line histograms represent cells from / mice, and broken line histograms represent cells from /
littermate controls. Results are representative of two independent experiments.
are consistent with previous observations that Jurkat Why heterozygous CARMA1 mutant T cells but not B
cells proliferated in response to mitogens is not clear.T cells deficient in CARMA1 secrete very little IL-2 in
response to PMA plus CD3 and CD28 crosslinking [3]. The CARD protein has been shown to act as a domi-
nant-negative inhibitor of TCR-induced NF-B activa-In the case of B cells, both heterozygous and homozy-
gous CARMA1 mutant B cells exhibited defective mito- tion in Jurkat T cells [1, 2]. Expression of CARD in the
heterozygous mice was determined by immunoprecipi-gen-induced proliferation. Uptake of [3H]-thymidine in
response to stimulation with anti-IgM or anti-CD40 anti- tation and Western blot analysis of whole spleen, so
one possibility is that the splicing of exon 1 to exon 4bodies or to LPS, either alone or in combination with
anti-IgM antibodies, was low to negligible, and unlike to generate the CARD transcript occurred less effi-
ciently in T cells than in B cells. Alternatively, becausethe proliferation of CARMA1 mutant T cells, proliferation
of the mutant B cells was not restored by exogenous IL-2 wild-type CARMA1 appears to be required for normal
B but not T cell development, the proliferative defect of(Figure 3B and data not shown). Thus, the lymphocyte
proliferative defect in the absence of wild-type CARMA1 heterozygous CARMA1 mutant B cells may reflect a
splenic B cell developmental defect not revealed byis different for B and T cells. Because purified resting B
and T cells isolated from homozygous CARMA1 mutant surface expression of B220 and IgM.
Previous studies using Jurkat T cells have indicatedmice underwent spontaneous apoptosis in culture at
the same rate as their wild-type counterparts (data not that CARMA1 is required for activation of NF-B tran-
scription factors in response to TCR ligation or stimula-shown), a general survival defect is unlikely to be re-
sponsible for their abnormal proliferative responses. tion with PMA and ionomycin [1–3]. The CARD of
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to Rel, RelA (also called p65) and NF-B1 (also called
p50) confirmed previous observations that the faster
migrating C2 complex consists predominantly of NF-
B1 homodimers, whereas the more slowly migrating
C1 complex probably consists of heterodimers of Rel,
RelA, and NF-B1 [8]. Induction of the C1 and C2 NF-
B complexes in homozygous CARMA1 mutant T cells
after 4 and 8 hr of stimulation was reduced, and in
contrast to findings in wild-type T cells, there was little
diminution in the amount of free probe at 8 hr. The low
level of NF-B DNA binding activity might explain why
proliferation in response to PMA and ionomycin is not
abolished completely (Figure 3A). Consistent with previ-
ous studies in Jurkat T cells [1, 2], these results indicate
that wild-type CARMA1 requires its CARD to mediate
normal NF-B activation in mitogen-stimulated primary
mouse T cells.
CARMA1 associates with Bcl-10 through a CARD-
CARD interaction [1–5], and Bcl-10-deficient lympho-
cytes are defective at NF-B activation after antigen
receptor ligation [9], suggesting that CARMA1 and
Bcl-10 act in the same pathway. Do homozygous
CARMA1 mutant mice completely resemble Bcl-10
knock-out mice? This question attempts to address
whether CARMA1 is the sole activator of Bcl-10 and
whether Bcl-10 is the only link between CARMA1 and
NF-B activation. CARMA1 and Bcl-10 mutant mice are
similar in that their T lymphocytes failed to activate NF-
B and proliferate in response to mitogens but differ in
that Bcl-10-deficient T cells were not rescued by the
addition of exogenous IL-2 [9]. B cells from both mutant
mice failed to proliferate in response to anti-IgM or anti-
CD40 antibodies, but only CARMA1 mutant B cells wereFigure 2. B Cell Defects in CARMA1 Mutant Mice
defective in their proliferative response to LPS. Interest-(A) CARMA1 mutant mice lack a peritoneal CD5 B cell population.
ingly, proliferation of heterozygous CARMA1 mutant BCells isolated from the peritoneal cavity of wild-type (/) and
cells in response to this particular stimulus, althoughhomozygous (/) CARMA1 mutant mice were stained with mono-
clonal antibodies against B220, IgM, and CD5 and analyzed by flow reduced relative to that of wild-type B cells, was not
cytometry. Dot plots show B220 and IgM staining after gating on completely inhibited, whereas no proliferation of hetero-
lymphocytes by their forward and side light-scattering profiles (up- zygous B cells was observed in response to IgM or CD40
per panel). Percentages indicate B220IgM cells. Histograms show
engagement (Figure 3B). Future studies will be neededCD5 expression after gating on B220IgM cells (lower panel). Re-
to address the nature of the requirement for CARMA1sults are representative of four mice of each genotype.
but not Bcl-10 in LPS responsiveness.(B) Naı¨ve CARMA1 mutant mice have reduced serum immunoglobu-
lin levels. Sera from nine 6-week-old / (open circles) and / Basal serum immunoglobulin levels were reduced in
(filled circles) mice were examined by isotype-specific ELISA. Levels both Bcl-10 and CARMA1 mutant mice, indicating that
of IgM, IgG2b, IgG3, and in some instances IgA were below detection both molecules are essential for normal humoral immu-
in / mice. Horizontal lines represent the mean serum Ig level.
nity. It was not reported whether Bcl-10-deficient mice
lack a CD5 peritoneal B cell population as observed
CARMA1 interacts with the CARD of Bcl-10 to recruit for CARMA1 mutant mice. However, consistent with a
Bcl-10 to the plasma membrane [1–5], and by an ill- role for CARMA1 in NF-B activation in B cells, de-
defined mechanism this leads to activation of the IB pressed serum immunoglobulin levels, reduced num-
kinase complex, which leads to phosphorylation, ubiqui- bers of CD5 B cells in the peritoneal cavity, and im-
tination, and degradation of the IBs that sequester paired mitogen-induced B cell proliferation also have
NF-B complexes in the cytosol [6, 7]. Activation of been reported for mice lacking both Rel and NF-B1
NF-B DNA binding activity in purified wild-type and transcription factors [10].
homozygous CARMA1 mutant T cells stimulated with One-third of Bcl-10-deficient embryos were reported
PMA and ionomycin was determined by an electropho- to die during embryonic development as a consequence
retic mobility shift assay (Figure 4). After 4 hr of stimula- of defective neural-tube closure [9]. The ratio of wild-
tion, wild-type T cells possessed elevated levels of two type:heterozygous:homozygous CARMA1 mutant mice
nuclear NF-B complexes (C1 and C2) able to bind to at 43:72:45 is close to the expected Mendelian fre-
a DNA probe containing the B3 binding site from the quency of 1:2:1, so defective embryogenesis in the ho-
murine rel promoter. Still greater upregulation of these mozygous CARMA1 mutant mice seems unlikely. CARMA1
complexes was observed for wild-type T cells after 8 hr is one of three proteins consisting of an N-terminal CARD
followed by regions predicted to form coiled coil, PDZ,of stimulation. Supershift experiments using antibodies
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Figure 3. B and T Cells from CARMA1 Mutant
Mice Exhibit Defective Mitogen-Induced Pro-
liferation
(A) Purified lymph node T cells from wild-type
(circles), heterozygous (triangles), and homo-
zygous (squares) CARMA1 mutant mice were
stimulated with plate-bound anti-CD3 and
anti-CD28 antibodies or 2 ng/mL PMA and
0.5 g/ml ionomycin in the presence and ab-
sence of 40 ng/ml recombinant mouse in-
terleukin-2 (rmIL-2). Proliferation was mea-
sured by [3H]-thymidine uptake for 6 hr on
the days indicated. Data points represent the
mean	 standard deviation of triplicate wells.
Results are representative of two indepen-
dent experiments.
(B) Purified spleen B cells from wild-type (cir-
cles), heterozygous (triangles), and homozy-
gous (squares) CARMA1 mutant mice were
stimulated with 20 g/ml anti-IgM or anti-
CD40 antibodies plus 40 ng/ml each of rmIL-2,
-4, and -5 and 20 g/ml LPS alone or in com-
bination with anti-IgM antibodies. Prolifera-
tion was measured by [3H]-thymidine uptake
for 6 hr on the days indicated.
(C) Exogenous IL-2 prevents mitogen-
induced apoptosis of CARMA1 mutant T cells
and allows cell growth. Purified lymph node
T cells from wild-type (/) and homozygous
(/) CARMA1 mutant mice were stimulated
with plate-bound anti-CD3 and anti-CD28
antibodies in the presence and absence of
rmIL-2 for 3 days, stained with propidium io-
dide (PI) and FITC-conjugated annexin-V, and
examined by flow cytometry (top panel). The
numbers on each dot plot represent the per-
centage of viable (FITC-negative, PI-nega-
tive) T cells. The forward light scatter profiles
of the viable cells give an indication of cell
size and are shown as histograms (bottom
panel). Solid-line histograms represent cells stimulated with mitogens for 3 days. Broken-line histograms represent cells prior to stimulation
at day 0. Results are representative of two independent experiments.
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Figure 4. NF-B DNA Binding Activity Is Diminished in Mitogen-
Stimulated CARMA1 Mutant T Cells
Nuclear extracts prepared from purified resting T cells (lanes 1, 4,
7, and 10) or purified T cells stimulated for 4 (lanes 2, 5, 8, and 11)
or 8 (lanes 3, 6, 9, and 12) hr with 2 ng/ml PMA and 0.5 g/ml
ionomycin were incubated with poly(dI.dC), followed by antibodies
of the indicated specificity, and then 32P-labeled B3 probe. The
resulting complexes were resolved in 6% polyacrylamide DNA retar-
dation gels. C1 and C2 are slow- and fast-mobility NF-B/B3 com-
plexes, respectively. Open arrowheads indicate nonspecific binding
to the B3 probe, and filled arrowheads indicate free B3 probe.
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